Regeneron beats Q2

Regeneron beats quarterly estimates on eczema drug strength, shares rise

Regeneron exceeded Q2 revenue and profit estimates, driven by a 38% increase in Dupixent sales and strong high-dose Eylea performance. Shares rose nearly 5% after reporting $4.29 billion in quarterly